Table 3: Baseline characteristics of trial participants*.
| Trial | Duration of diabetes, yr | Age, yr | HbA1c, % | Body mass index |
|---|---|---|---|---|
| ADOPT, 200620–26† |
Expressed in publication as: < 1 yr; 1–2 yr; and > 2 yr. Participants had to be diagnosed with type 2 diabetes within 3 yr from screening to trial |
SU: 56.4 ± 10.2 M: 57.9 ± 9.9 |
SU: 7.4 ± 0.9 M: 7.4 ± 0.9 |
SU: 32.3 ± 6.3 M: 32.1 ± 6.1 |
| Campbell et al., 199427 |
2.8 (3.9) / 2.3 (3.2) |
SU: 57 ± 9.0 M: 57 ± 10.0 |
SU: 11.8 ± 2.1 M: 11.5 ± 1.9 |
SU: 31.2 ± 6.6 M: 29.6 ± 5.6 |
| Collier et al., 198928 |
All newly diagnosed |
SU: 55.5 ± 5.1 M: 53.1 ± 5.1 |
SU: 11.7 ± 1.5 M: 12.1 ± 2.4 |
SU: 23.1 ± 1.3 M: 24.3 ± 1.4 |
| DeFronzo et al., 199529‡ |
8.7 (5.8) / 8.4 (5.8) |
SU: 56 ± 14.5 M: 55 ± 14.5 |
SU: 8.5 ± 1.4 M: 8.9 ± 1.4 |
SU: 29.1 ± 4.3 M: 29.0 ± 4.3 |
| Derosa et al., 200442 |
NR, but diabetes had to be diagnosed within 6 mo of enrolment |
SU: 54 ± 10.0 M: 56 ± 9.0 |
SU: 8.5 ± 1.2 M: 8.4 ± 1 |
SU: 27.6 ± 1.2 M: 28.1 ± 1.5 |
| Hermann et al., 1991a30§ |
All patients: 7.6 (range 4 mo to 24 yr) |
All patients: 58.9 ± 8.8 |
SU: 8.1 ± 1.0 M: 7.9 ± 1.6 |
All patients: 26.2 ± 3.8 |
| Hermann et al., 1991b31–34 |
All patients: 3.6 (range 0–38) |
All patients: 59.4 ± 8.8 |
SU: 6.7 ± 1.7 M: 6.9 ± 1.8 |
All patients: 28.3 ± 4.6 |
| Kamel et al., 199735 |
NR |
NR |
Gliclazide: 8.4 ± 1.1 Glibenclamide: 8.4 ± 1.1 M: 8.4 ± 0.5 |
NR |
| Lawrence et al., 200436** |
NR |
SU: 63.5 ± 11.4 M: 59.5 ± 9.3 |
SU: 7.9 ± 0.9 M: 8.0 ± 0.9 |
SU: 28.7 (28.3–34.4)** M: 29.2 (28.1–31.6)** |
| Tang et al., 200441 |
NR |
SU: 56.4 ± 8.8 M: 53.8 ± 9.7 |
SU: 6.8 ± 1.6 M: 7.2 ± 1.4 |
SU: 23.3 ± 1.7 M: 24.6 ± 2.2 |
| Tessier et al., 199937†† |
SU: 4.7 ± 6.1 M: 5.4 ± 6.5 |
SU: 59.3 ± 7.3 M: 59.1 ± 7.1 |
SU: 7.8 ± 1.8 M: 7.1 ± 1.7 |
SU: 28.6 ± 4.0 M: 29.3 ± 3.0 |
| Tosi et al., 200338 |
SU: 9.9 ± 6.6 M: 11.2 ± 9.6 |
SU: 57.9 ± 7.5 M: 58.2 ± 7.3 |
SU: 7.9 ± 1.0 M: 7.7 ± 0.9 |
SU: 26.3 ± 2.3 M: 26.4 ± 2.7 |
| UKPDS 34, 19982,39,40 |
All newly diagnosed |
SU: 53 ± 9.0 M: 53 ± 8.0 |
SU: 7.2 ± 1.5 M: 7.3 ± 1.5 |
SU: 31.5 ± 4.4 M: 31.6 ± 4.2 |
| Yamanouchi et al., 200543 | SU: 3.3 ± 2.6 M: 3.0 ± 2.5 |
SU: 55.6 ± 9.3 M: 54.7 ± 9.8 |
SU: 9.8 ± 0.7 M: 9.9 ± 0.7 |
SU: 25.6 ± 3.5 M: 26.2 ± 3.8 |
Note: ADOPT = A Diabetes Outcome Progression Trial, HbA1c = glycosylated hemoglobin, M = metformin, NR = not reported, SU = sulfonylurea, UKPDS = United Kingdom Prospective Diabetes Study. *Values are reported as means and standard deviations, unless stated otherwise. †Baseline characteristics reported only for the participants who received a dose of the study drug (glibenclamide 1441, rosiglitazone 1456, metformin 1454). ‡Standard deviations were calculated from standard errors. Fasting plasma glucose levels were converted from mg/dL to mmol/L. §Baseline characteristics reported only for the 22 participants who completed the trial. ¶Standard deviations for HbA1c concentration were calculated from standard errors. **Baseline variables reported only for the participants who completed the trial (20 in each intervention arm). Median (interquartile range) for body mass index. ††Baseline characteristics reported only for the participants who completed the trial (36 of 39).